Source-grounded facts extracted from KESTRA MEDICAL TECHNOLOGIES, LTD.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
KESTRA MEDICAL TECHNOLOGIES, LTD. reported the third quarter fiscal 2026, which ended January 31, 2026 results: revenue $24.6 million, net income $34.2 million. Guidance raised.
“and digital healthcare company, today reported financial results for the third quarter fiscal 2026, which ended January 31, 2026. Financial Highlights • Generated revenue of $24.6 million in Q3 FY26, an increase of 63% compared to the prior year period. • Expanded gross margin to 52.6% in Q3 FY26 compared to 43.4% in the prior year period. • Increased FY26 revenue”
Material Agreements
KESTRA MEDICAL TECHNOLOGIES, LTD. entered into Underwriting Agreement with BofA Securities, Inc., Piper Sandler & Co., J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC, as representatives of the several underwriters named therein valued at approximately $148.4 million (effective 2025-12-02).
“On December 2, 2025, Kestra Medical Technologies, Ltd., a Bermuda exempted company (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with BofA Securities, Inc., Piper Sandler & Co., J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC, as representatives of the several underwriters named therein (collectively, the “ Underwriters ”), related to an underwritten public offering (the “ Offering ”) of 6,900,000 common shares, par value $1.00 per share (the “ Common Shares ”), at a purchase price per share of $23.00 (the “ Offering Price ”).”
Conor Hanley was elected as Director at KESTRA MEDICAL TECHNOLOGIES, LTD..
“On June 4, 2025, the Board of Directors (the “Board”) of Kestra Medical Technologies, Ltd. (the “Company”) elected Mr. Conor Hanley as a new member of the Board.”
Governance Changes
KESTRA MEDICAL TECHNOLOGIES, LTD.: The company's Amended and Restated bye-laws became effective (effective 2025-03-07).
“On March 7, 2025, the Company’s Amended and Restated bye-laws (the “ bye-laws ”), in the form previously filed as Exhibit 3.3 to the Registration Statement, became effective.”
Governance Changes
KESTRA MEDICAL TECHNOLOGIES, LTD.: The company increased authorized share capital to US$100,000,000 divided into 100,000,000 common shares and redesignated ordinary shares as common shares (effective 2025-03-07).
“As previously disclosed in the Registration Statement, in connection with the Offering, the Company’s Board of Directors and its sole shareholder approved, among other things, an increase to the Company’s authorized share capital to US$100,000,000 divided into 100,000,000 common shares of par value of US$1.00 each and a redesignation of the Company’s authorized and issued ordinary shares as common shares.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.